SCLC, EXTENSIVE STAGE

This study is testing whether adding an oral chemotherapy pill (etoposide capsules) to an immunotherapy drug (adebrelimab) can help control extensive-stage small cell lung cancer after initial treatment. The trial will involve 32 patients in China whose cancer hasn't gotten worse…

This study is testing whether adding a new drug called golidocitinib to standard immunotherapy (PD-1 inhibitors) can help control extensive-stage small cell lung cancer for longer. After initial chemotherapy, participants receive the two-drug combination as maintenance therapy to…

This trial is testing whether adding a drug called niraparib to standard immunotherapy maintenance can help control advanced small cell lung cancer for longer. It is for patients whose cancer has a specific biomarker (SLFN11-positive) and has not worsened after initial chemothera…

This early-stage study is testing the safety and initial effectiveness of a new combination treatment for advanced small cell lung cancer. It combines a radioactive drug that targets specific tumor markers with an immunotherapy drug, given as a maintenance therapy after initial c…

This study is testing whether adding a new immunotherapy drug called HLX10 to standard chemotherapy helps control advanced small cell lung cancer. It is for Japanese patients who have not yet received any treatment for their extensive-stage cancer. The main goal is to see how wel…

This study is testing an experimental daily pill called ABP1011T for people with advanced solid tumors, like certain lung, esophageal, and cervical cancers, who have already tried and stopped responding to standard treatments. The main goal is to see if the pill can shrink tumors…

This study is testing whether adding a modified virus called Olvi-Vec to standard chemotherapy can help control advanced small cell lung cancer that has returned or stopped responding to previous platinum-based treatments. The research aims to see if this combination is safe and …